“…The global spread of a new type of coronavirus, SARS-CoV-2, causing the respiratory disease COVID-19 [ 1 , 2 , 3 , 4 ] mobilized both the public and private sector and resulted in a rapid development of solutions focused on SARS-CoV-2 detection and analysis. Next to a number of solutions utilizing the advantages of RT-qPCR techniques for SARS-CoV-2 detection [ 5 , 6 ], the next-generation sequencing (NGS)-based protocols allows the analysis of SARS-CoV-2 genome evolution and variability and the monitoring of its spread within the global population (Nextstrain; ) [ 7 , 8 ]. These knowledges address the need to elucidate its genomic characteristics (GISAID; ) in order to ensure the efficiency of RT-qPCR testing, assess its transmission through clonal events, and develop a reliable vaccination protocols future therapies, especially considering the fact that RNA viruses are prone to accumulate variants in its genome in a relatively short timeline, which in the case of SARS-CoV-2 is also related to its capacity to proofread and remove mismatched nucleotides during genome replication and transcription [ 9 , 10 , 11 , 12 ].…”